In silico Discovery of Resveratrol Analogues as Potential Agents in Treatment of Metabolic Disorders

Author(s): Nebojša Pavlović*, Maja Đanić, Bojan Stanimirov, Svetlana Goločorbin-Kon, Karmen Stankov, Mladena Lalić-Popović, Momir Mikov.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 35 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Resveratrol was demonstrated to act as partial agonist of PPAR-γ receptor, which opens up the possibility for its use in the treatment of metabolic disorders. Considering the poor bioavailability of resveratrol, particularly due to its low aqueous solubility, we aimed to identify analogues of resveratrol with improved pharmacokinetic properties and higher binding affinities towards PPAR-γ.

Methods: 3D structures of resveratrol and its analogues were retrieved from ZINC database, while PPAR-γ structure was obtained from Protein Data Bank. Docking studies were performed using Molegro Virtual Docker software. Molecular descriptors relevant to pharmacokinetics were calculated from ligand structures using VolSurf+ software.

Results: Using structural similarity search method, 56 analogues of resveratrol were identified and subjected to docking analyses. Binding energies were ranged from -136.69 to -90.89 kcal/mol, with 16 analogues having higher affinities towards PPAR-γ in comparison to resveratrol. From the calculated values of SOLY descriptor, 23 studied compounds were shown to be more soluble in water than resveratrol. However, only two tetrahydroxy stilbene derivatives, piceatannol and oxyresveratrol, had both better solubility and affinity towards PPAR-γ. These compounds also had more favorable ADME profile, since they were shown to be more metabolically stable and wider distributed in body than resveratrol.

Conclusion: Piceatannol and oxyresveratrol should be considered as potential lead compounds for further drug development. Although experimental validation of obtained in silico results is required, this work can be considered as a step toward the discovery of new natural and safe drugs in treatment of metabolic disorders.

Keywords: Molecular docking, PPAR, resveratrol, descriptors, ADME, pharmacoinformatics.

[1]
Huang THW, Teoh AW, Lin BL, Lin DSH, Roufogalis B. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol Res 2009; 60(3): 195-206.
[http://dx.doi.org/10.1016/j.phrs.2009.03.020] [PMID: 19646659]
[2]
Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm 2013; 2013549627
[http://dx.doi.org/10.1155/2013/549627] [PMID: 23781121]
[3]
Ivanova EA, Myasoedova VA, Melnichenko AA, Orekhov AN. Peroxisome Proliferator-Activated Receptor (PPAR) gamma agonists as therapeutic agents for cardiovascular disorders: focus on atherosclerosis. Curr Pharm Des 2017; 23(7): 1119-24.
[http://dx.doi.org/10.2174/1381612823666161118145850] [PMID: 27855608]
[4]
Villacorta L, Schopfer FJ, Zhang J, Freeman BA, Chen YE. PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) 2009; 116(3): 205-18.
[http://dx.doi.org/10.1042/CS20080195] [PMID: 19118492]
[5]
Janesick A, Blumberg B. Minireview: PPARγ as the target of obesogens. J Steroid Biochem Mol Biol 2011; 127(1-2): 4-8.
[http://dx.doi.org/10.1016/j.jsbmb.2011.01.005] [PMID: 21251979]
[6]
Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014; 20(4): 573-91.
[http://dx.doi.org/10.1016/j.cmet.2014.08.005] [PMID: 25242225]
[7]
Wang L, Waltenberger B, Pferschy-Wenzig EM, et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol 2014; 92(1): 73-89.
[http://dx.doi.org/10.1016/j.bcp.2014.07.018] [PMID: 25083916]
[8]
Calleri E, Pochetti G, Dossou KSS, et al. Resveratrol and its metabolites bind to PPARs. ChemBioChem 2014; 15(8): 1154-60.
[http://dx.doi.org/10.1002/cbic.201300754] [PMID: 24796862]
[9]
Inoue H, Jiang XF, Katayama T, Osada S, Umesono K, Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor α in mice. Neurosci Lett 2003; 352(3): 203-6.
[http://dx.doi.org/10.1016/j.neulet.2003.09.001] [PMID: 14625020]
[10]
Murtaza G, Latif U, Najam-Ul-Haq M, et al. Resveratrol: An active natural compound in red wines for health. Yao Wu Shi Pin Fen Xi 2013; 21: 1-12.
[11]
Arora D, Jaglan S. Therapeutic applications of resveratrol nanoformulations. Environ Chem Lett 2018; 16: 35-41.
[http://dx.doi.org/10.1007/s10311-017-0660-0]
[12]
Rauf A, Imran M, Suleria HAR, Ahmad B, Peters DG, Mubarak MS. A comprehensive review of the health perspectives of resveratrol. Food Funct 2017; 8(12): 4284-305.
[http://dx.doi.org/10.1039/C7FO01300K] [PMID: 29044265]
[13]
Wahl D, Bernier M, Simpson SJ, de Cabo R, Le Couteur DG. Future directions of resveratrol research. Nutr Healthy Aging 2018; 4(4): 287-90.
[http://dx.doi.org/10.3233/NHA-170035] [PMID: 29951589]
[14]
Brasnyó P, Molnár GA, Mohás M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011; 106(3): 383-9.
[http://dx.doi.org/10.1017/S0007114511000316] [PMID: 21385509]
[15]
Davidov-Pardo G, McClements DJ. Resveratrol encapsulation: designing delivery systems to overcome solubility, stability and bioavailability issues. Trends Food Sci Technol 2014; 38: 88-103.
[http://dx.doi.org/10.1016/j.tifs.2014.05.003]
[16]
Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release 2012; 158(2): 182-93.
[http://dx.doi.org/10.1016/j.jconrel.2011.09.083] [PMID: 21978644]
[17]
de Vries K, Strydom M, Steenkamp V. Bioavailability of resveratrol: possibilities for enhancement. J Herb Med 2018; 11: 71-7.
[http://dx.doi.org/10.1016/j.hermed.2017.09.002]
[18]
Neves AR, Lúcio M, Lima JLC, Reis S. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Curr Med Chem 2012; 19(11): 1663-81.
[http://dx.doi.org/10.2174/092986712799945085] [PMID: 22257059]
[19]
Nawaz W, Zhou Z, Deng S, et al. Therapeutic versatility of resveratrol derivatives. Nutrients 2017; 9(11): 9.
[http://dx.doi.org/10.3390/nu9111188] [PMID: 29109374]
[20]
Lewis SN, Bassaganya-Riera J, Bevan DR. Review article: virtual screening as a technique for PPAR modulator discovery. PPAR Res 2010; 2010861238
[http://dx.doi.org/10.1155/2010/861238] [PMID: 19746174]
[21]
Lu IL, Huang CF, Peng YH, et al. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. J Med Chem 2006; 49(9): 2703-12.
[http://dx.doi.org/10.1021/jm051129s] [PMID: 16640330]
[22]
Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000; 28(1): 235-42.
[http://dx.doi.org/10.1093/nar/28.1.235] [PMID: 10592235]
[23]
Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: A free tool to discover chemistry for biology. J Chem Inf Model 2012; 52(7): 1757-68.
[http://dx.doi.org/10.1021/ci3001277] [PMID: 22587354]
[24]
Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006; 49(11): 3315-21.
[http://dx.doi.org/10.1021/jm051197e] [PMID: 16722650]
[25]
Singh SP, Konwar BK. Virtual screening and molecular descriptor analysis on dietary phytochemicals against heat shock protein 90 enzyme. Lett Drug Des Discov 2014; 11: 40-9.
[http://dx.doi.org/10.2174/15701808113109990044]
[26]
Kerns EH, Di L. Rules for Rapid Property Profiling from StructureDrug-like Properties: Concepts, Structure Design and Methods. San Diego: Academic Press 2008; pp. 37-42.
[http://dx.doi.org/10.1016/B978-012369520-8.50005-X]
[27]
Tian S, Wang J, Li Y, Li D, Xu L, Hou T. The application of in silico drug-likeness predictions in pharmaceutical research. Adv Drug Deliv Rev 2015; 86: 2-10.
[http://dx.doi.org/10.1016/j.addr.2015.01.009] [PMID: 25666163]
[28]
Cruciani G, Pastor M, Guba W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 2000; 11(Suppl. 2): S29-39.
[http://dx.doi.org/10.1016/S0928-0987(00)00162-7] [PMID: 11033425]
[29]
Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL. Quantifying the chemical beauty of drugs. Nat Chem 2012; 4(2): 90-8.
[http://dx.doi.org/10.1038/nchem.1243] [PMID: 22270643]
[30]
Selvaraj G, Kaliamurthi S, Thirugnanasambandam R. Molecular docking studies on potential PPAR-γ agonist from Rhizophora apiculata. Bangladesh J Pharmacol 2014; 9: 298-302.
[http://dx.doi.org/10.3329/bjp.v9i3.18915]
[31]
Xu XY, Cheng F, Shen JH, et al. Agonist-PPARγ interactions: Molecular modeling study with docking approach. Int J Quantum Chem 2003; 93: 405-10.
[http://dx.doi.org/10.1002/qua.10575]
[32]
Mirza MU, Mirza AH, Ghori NU, Ferdous S. Glycyrrhetinic acid and E.resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson’s disease: a pharmacoinformatics study. Drug Des Devel Ther 2014; 9: 187-98.
[http://dx.doi.org/10.2147/DDDT.S72794] [PMID: 25565772]
[33]
Rastogi H, Jana S. Evaluation of physicochemical properties and intestinal permeability of six dietary polyphenols in human intestinal colon adenocarcinoma Caco-2 cells. Eur J Drug Metab Pharmacokinet 2016; 41(1): 33-43.
[http://dx.doi.org/10.1007/s13318-014-0234-5] [PMID: 25351179]
[34]
Piotrowska H, Kucinska M, Murias M. Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat Res 2012; 750(1): 60-82.
[http://dx.doi.org/10.1016/j.mrrev.2011.11.001] [PMID: 22108298]
[35]
Youn J, Lee JS, Na HK, Kundu JK, Surh YJ. Resveratrol and piceatannol inhibit iNOS expression and NF-kappaB activation in dextran sulfate sodium-induced mouse colitis. Nutr Cancer 2009; 61(6): 847-54.
[http://dx.doi.org/10.1080/01635580903285072] [PMID: 20155626]
[36]
Sangsen Y, Likhitwitayawuid K, Sritularak B, Wiwattanawongsa K, Wiwattanapatapee R. Novel solid lipid nanoparticles for oral delivery of oxyresveratrol: effect of the formulation parameters on the physicochemical properties and in vitro release. Int J Med Pharm Sci Eng 2013; 7: 506-13.
[37]
Weber JT, Lamont M, Chibrikova L, et al. Potential neuroprotective effects of oxyresveratrol against traumatic injury. Eur J Pharmacol 2012; 680(1-3): 55-62.
[http://dx.doi.org/10.1016/j.ejphar.2012.01.036] [PMID: 22489319]
[38]
Chen W, Yeo SCM, Elhennawy MGAA, Lin HS. Oxyresveratrol: A bioavailable dietary polyphenol. J Funct Foods 2016; 22: 122-31.
[http://dx.doi.org/10.1016/j.jff.2016.01.020]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 35
Year: 2019
Page: [3776 - 3783]
Pages: 8
DOI: 10.2174/1381612825666191029095252
Price: $65

Article Metrics

PDF: 15
HTML: 3